Latest Content

Sanofi is appointing Belén Garijo chief as director and chief executive officer after its annual meeting, underscoring the company's leadership and governance changes.

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single adaptive engine.

Jessica Lovett, VP of commercial strategy and innovation at Innomar, discusses the importance of meeting the needs of everyone at the table.

In the second part of his interview, Jeff Golfman notes how shelf-life constraints and shipping delays heighten drug shortage risk, prompting calls for diversified sourcing and larger inventory buffers.

Kaida Biopharma’s chair and acting CEO discusses how President Trump’s MFN policies and other regulatory actions are impacting pharma’s ability to invest in new treatments and adjusting international launch strategies.

In today's Pharmaceutical Executive Daily, Rocket Pharmaceuticals announces a $180 million sale of its rare pediatric disease priority review voucher, Teva Pharmaceutical enters a definitive agreement to acquire Emalex Biosciences for up to $900 million, and a feature article examines the pharmaceutical supply chain risks converging around the Strait of Hormuz.

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Teva will acquire Emalex to add ecopipam, a late-stage pediatric Tourette syndrome candidate, ahead of a planned 2026 filing.

In an exclusive Q&A at Asembia’s AXS26 Summit, Syneos Health's vice president of strategic market access and patient support Kim Plesnarski touches on rapid digital innovation, evolving market structures, and shifting regulatory pressures.

In the final part of her interview, Plesnarski notes how market access strategies evolve into core launch drivers as IRA timelines, pricing pressures, and digital adherence tools reshape how companies maximize value.

Dr. Stella Vnook explains how pharma pricing is likely to be impacted by various regulatory actions, such as MFN.

In the first part of his interview, Jeff Golfman, notes how The Strait of Hormuz disruption exposes broader global supply chain contraction, raising risks for vaccines, cancer therapies, and other critical medicines.

In today's Pharmaceutical Executive Daily, we cover Sun Pharma and IMG Pharma's respective acquisitions, FDA's approval of AstraZeneca's Breztri, and a new feature examining why Ireland has become one of the pharmaceutical industry's most strategically important global manufacturing hubs.